Kilitch Drugs Posts Stellar Q1 FY26 Performance with Massive Profit Surge.

Kilitch Drugs delivered an exceptional set of numbers for the June 2025 quarter, with strong revenue growth and an extraordinary jump in profitability. Sales grew 29% YoY to ₹43.1 crore from ₹33.4 crore in June 2024. EBIDT almost doubled, up 96% to ₹3.26 crore from ₹1.66 crore, reflecting improved operating efficiency. Net profit skyrocketed 1964% YoY to ₹2.27 crore from just ₹0.11 crore last year, while EPS jumped 125% to ₹1.73 from ₹0.77. Kilitch is setting up a greenfield facility at Khopoli, aimed at in-house production of injectables, eye-drops, oral solid dosage forms, and nutraceuticals. This move is expected to reduce outsourcing costs, broaden product range, and improve margins over time. At a market price of ₹434 and market cap of ₹759 crore, the stock trades at a PE of 28.4, supported by its sharp earnings improvement. Key takeaway: The company has delivered a turnaround quarter, with robust sales growth and exponential profit expansion, indicating strong operational momentum heading into FY26.